Compare Lumen Technologies Inc (LUMN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Lumen Technologies Inc trades at $6.8 (market cap $6.47B), while Regeneron Pharmaceuticals Inc trades at $672.86 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 10.9× Lumen Technologies Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| LUMN | REGN | |
|---|---|---|
Market Cap | $6.47B | $70.47B |
Sector | Media | Health |
52-Week High | $11.83 | $812.27 |
52-Week Low | $3.70 | $545.46 |
Enterprise Value | $18.10B | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $6.275, down 0.08% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of $1.74B in 2025 despite beating EPS estimates in two of the last three quarters. Recent news highlights strategic acquisitions like Alkira to bolster its AI networking capabilities, while the balance sheet shows high debt levels of $17.49B long-term.
The outlook remains challenging due to persistent losses and heavy debt, though cost-cutting initiatives and a $13B contract backlog offer potential upside. Analyst consensus is cautious with a $8.25 price target, but the stock's deep value (P/S 0.52) may attract contrarians if EBITDA improves. Key risks include execution on turnaround plans and interest expense pressure.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
